P2.01-18 ORION: Durvalumab+Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

Autor:	M. Marcovitz, T. Improta, K. Dipiazza, M. Lanasa, Y. Liu, Myung-Ju Ahn
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Durvalumab business.industry Stage IV non-small cell lung cancer Olaparib chemistry.chemical_compound Maintenance therapy chemistry Internal medicine medicine business
Zdroj:	Journal of Thoracic Oncology. 14:S645-S646
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2019.08.1362
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f9b14dd853a6b0e5d7e07a1137d410d2 https://doi.org/10.1016/j.jtho.2019.08.1362 Zobrazit plný text záznamu